Kura Oncology, Inc.

Day range

$9.62 – $9.84

Open

$9.73

Prev close

$9.61

Volume

411.99K

Market cap

$854.91M

Shares out

88.96M

P/E

—

P/S

11.07

P/B

17.65

P/FCF

—

ROE

-612.8%

ROA

-50.5%

Debt/Equity

0.20

Div yield

0.00%

As of Oct 23, 2026

• Private placementSep 9, 2026

  On September 8, 2026, Caspian completed the sale and issuance of $50.0 million of shares of its Series A preferred stock in a private financing (the “Series A Financing”). The Company invested $4.3 million in the Series A Financing.

• Executive compensation changeSep 8, 2026

  In connection with Ms. Fulk's appointment, the Company entered into an employment agreement with Ms. Fulk on September 8, 2026 ... Ms. Fulk is (i) entitled to an annual base salary of $550,000, (ii) eligible to receive an annual discretionary bonus of up to 45% of her then current base salary, (iii) entitled to receive an option to purchase 450,000 shares ... and (iv) entitled to receive a one-time performance-based restricted stock unit award covering 173,438 shares.

• Executive compensation changeJul 29, 2026

  On July 24, 2026, Kura Oncology, Inc. entered into a Second Amended and Restated Executive Employment Agreement with Troy E. Wilson, Ph.D., J.D., the Company's Chairman, President and Chief Executive Officer to, among other things, modify certain severance provisions. On July 27, 2026, the Company entered into an Amended and Restated Executive Employment Agreement with Brian Powl, the Company's Chief Commercial Officer and an Amended and Restated Executive Employment Agreement with Kathleen Ford, the Company's Chief Operating Officer, in each case to, among other things, modify certain severance provisions.

• Equity compensation grantJun 4, 2026

  amended the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (the '2014 Plan') and the 2015 Employee Stock Purchase Plan (the 'ESPP')... to increase the number of shares of our common stock authorized for issuance under the 2014 Plan by 6,500,000 shares and increase the number of shares of our common stock authorized for issuance under the ESPP by 2,500,000 shares

• Bylaw amendmentJan 29, 2026

  On January 28, 2026, the board of directors (the "Board") of Kura Oncology, Inc. (the "Company") adopted amended and restated bylaws of the Company (as amended and restated, the "A&R Bylaws"), effective as of such adoption date. The following is a summary of the material changes made to the Company's amended and restated bylaws...

Days to cover

7.7

Short interest

14.42M

Avg volume

1.86M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
  positiveZacks Investment Research· Sep 1, 2026
• Kura Oncology to Report Second Quarter Financial Results
  positiveGlobeNewswire Inc.· Aug 5, 2026
• Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
  positiveGlobeNewswire Inc.· Apr 24, 2026
• Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
  positiveGlobeNewswire Inc.· Apr 17, 2026
• Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· Apr 3, 2026